Document ID: chunk:federal_register_of_legislation:F2023L00941:reg:9:p5
Version: federal_register_of_legislation:F2023L00941
Segment Type: reg
Provision Reference: reg 9 (pt 5/6)
Character Range: 15505–18548

year before the clinical worsening of peripheral neuropathy; and
(b)          where exposure has ceased before the clinical worsening of peripheral neuropathy, then that worsening occurred within 3 months of cessation;
Note: specified list of chemicals (long term exposure) is defined in the Schedule 1 - Dictionary.
(47)      having a severe substance use disorder involving inhalation of a substance from the specified list of substances at the time of the clinical worsening of peripheral neuropathy;
Note: severe substance use disorder and specified list of substances are defined in the Schedule 1 - Dictionary.
(48)      inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) within the 30 days before the clinical worsening of peripheral neuropathy;
Note: inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) is defined in the Schedule 1 - Dictionary.
(49)      having an episode of acute cholinergic poisoning from exposure to an organophosphorus compound or a carbamate insecticide within the 2 months before the clinical worsening of peripheral neuropathy;
Note: acute cholinergic poisoning and organophosphorus compound are defined in the Schedule 1 - Dictionary.
(50)      being poisoned with an agent from the specified list of agents, as demonstrated by clinical, haematological or biochemical evidence, within the 30 days before the clinical worsening of peripheral neuropathy;
Note: specified list of agents is defined in the Schedule 1 - Dictionary.
(51)      having a nutritional deficiency as specified at the time of the clinical worsening of peripheral neuropathy;
Note: nutritional deficiency as specified is defined in the Schedule 1 - Dictionary.
(52)      having hypophosphataemia while undergoing total parenteral nutrition at the time of the clinical worsening of peripheral neuropathy;
(53)      taking a drug from the specified list of drugs that cannot be ceased or substituted, at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of drugs that cannot be ceased or substituted is defined in the Schedule 1 - Dictionary.
(54)      taking a drug that cannot be ceased or substituted and which is associated in the individual with the clinical worsening of peripheral neuropathy during drug therapy and either:
(a)          the improvement of peripheral neuropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of peripheral neuropathy on rechallenge with the same drug or another drug from the same class of drugs; and
where the drug was being taken at the time of the clinical worsening of peripheral neuropathy;
(55)      taking a drug from the specified list of drugs at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(56)      taking a drug which is associated in the individual with